



Revision date 07-Oct-2022 Version 2 Page 1/10

# Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

#### 1.1. Product identifier

Product Name HEPARIN SODIUM- heparin sodium injection, solution (Hospira, Inc.)

Product Code(s) PZ03547

Trade Name: Heparin Sodium Injection Solution

Chemical Family: Mixture

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as anticoagulant agent

#### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Pfizer Ireland Pharmaceuticals
OSG Building

Lake Forest, Illinois 60045 Ringaskiddy, Co. Cork.

1-800-879-3477 Ireland

+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

### Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous according to Regulation (EC) 1272/2008 and/or other applicable regulations.

2.2. Label elements

Signal word Not classified

**Hazard statements** Not classified in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients

(see Section 8).

Product Name HEPARIN SODIUM- heparin sodium injection, solution

(Hospira, Inc.)

Revision date 07-Oct-2022 Version 2

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Page 2/10

### Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances Not applicable

### 3.2 Mixtures

NonHazardous

Titorii iazaraeas	144 : 14 04	DEAGU	E0.11	1 01 10 11			
Chemical name	Weight-%	REACH	EC No	Classification	Specific	M-Factor	M-Factor
		Registration		according to	concentration		(long-term)
		Number		Regulation	limit (SCL)		`
				(EC) No.	(222)		
				1272/2008			
				[CLP]			
Water	*	-	231-791-2	Not classified	Not Listed	No data	No data
(CAS #: 7732-18-5)				as hazardous		available	available
Dalteparin Sodium	50 or 100 USP		Not Listed	Not classified	Not Listed	No data	No data
(Heparin Sodium)	units/mL			as hazardous		available	available
(CAS #: 9041-08-1)							
SODIUM CHLORIDE	*	-	231-598-3	Not classified	Not Listed	No data	No data
(CAS #: 7647-14-5)				as hazardous		available	available
Edetate disodium	*		205-358-3	Not classified	Not Listed	No data	No data
(CAS #: 139-33-3)				as hazardous		available	available

### Full text of H- and EUH-phrases: see section 16

**Acute Toxicity Estimate** 

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist -	Inhalation LC50 - 4 hour - vapor - mg/L	
			mg/L	Tiodi vapoi iligiz	nour gao ppin
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Dalteparin Sodium (Heparin Sodium) 9041-08-1	> 5000	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3000	10000	No data available	No data available	No data available
Edetate disodium 139-33-3	2000	No data available	No data available	No data available	No data available

### **Additional information**

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as

<sup>\*</sup> Proprietary

Product Name HEPARIN SODIUM- heparin sodium injection, solution

(Hospira, Inc.)

Revision date 07-Oct-2022 Version 2

a trade secret.

### **Section 4: FIRST AID MEASURES**

#### 4.1. Description of first aid measures

**Inhalation** Remove to fresh air. Seek immediate medical attention/advice.

**Eye contact** Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.

Consult a physician.

**Skin contact** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do

not induce vomiting unless directed by medical personnel. Seek medical attention

Page 3/10

immediately.

### 4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and

effects

For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

#### 4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

### Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

Suitable Extinguishing Media As for primary cause of fire.

### 5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the

chemical

Not applicable.

Hazardous combustion products This material produces toxic fumes of nitrogen and sulfur oxides, carbon dioxide, and

carbon monoxide during fires.

5.3. Advice for firefighters

Special protective equipment for

fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout

gear. Use personal protection equipment.

### Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

6.2. Environmental precautions

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be

taken to avoid environmental release.

Page 4/10

Product Name HEPARIN SODIUM- heparin sodium injection, solution

(Hospira, Inc.)

Revision date 07-Oct-2022 Version 2

\_\_\_\_\_

### 6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean

spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

### Section 7: HANDLING AND STORAGE

#### 7.1. Precautions for safe handling

### Advice on safe handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

### 7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical product used as. anticoagulant agent.

### Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

#### **Exposure Limits**

Refer to available public information for specific member state Occupational Exposure Limits.

## Dalteparin Sodium (Heparin Sodium)

Pfizer OEL TWA-8 Hr: 200 µg/m<sup>3</sup>

**SODIUM CHLORIDE** 

Latvia 5 mg/m³
Russia MAC: 5 mg/m³

**Edetate disodium** 

Russia MAC: 2 mg/m<sup>3</sup>

**Pfizer Occupational Exposure Band** 

(OEB) Statement: The purpose of the Occupational Exposure Band (OEB) classification system is to separate

substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to

revision when new information becomes available.

SODIUM CHLORIDE

Pfizer Occupational Exposure OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Band (OEB):

8.2. Exposure controls

Engineering controls Engineering controls should be used as the primary means to control exposures. General

\_\_\_\_\_

Product Name HEPARIN SODIUM- heparin sodium injection, solution

(Hospira, Inc.)

Revision date 07-Oct-2022 Version 2

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Page 5/10

**Environmental exposure controls** No information available.

Personal protective equipment Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in

the workplace and specific operational processes.

**Eye/face protection** Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection Impervious disposable protective clothing is recommended if skin contact with drug product

is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter).

(Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10

or international equivalent.).

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

### Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state Solution Color Colorless

Odor No information available.
Odor threshold No information available

Molecular formulaMixtureMolecular weightMixture

Property Values 5.0-7.5

Melting point / freezing point No data available

Boiling point / boiling range

Flash point No information available

Evaporation rate
No data available
Flammability (solid, gas)
No data available

Flammability Limit in Air

Upper flammability limit: No data available

Lower flammability limit: No data available

Vapor pressureNo data availableVapor densityNo data availableRelative densityNo data availableWater solubilityNo data availableSolubility(ies)Soluble Water

Page 6/10

Product Name HEPARIN SODIUM- heparin sodium injection, solution

(Hospira, Inc.)

Revision date 07-Oct-2022 Version 2

Partition coefficient No data available **Autoignition temperature** No data available **Decomposition temperature** No data available Kinematic viscosity No data available No data available **Dynamic viscosity** 

Particle characteristics

No information available Particle Size **Particle Size Distribution** No information available **Explosive properties** No information available

### 9.2. Other information

No information available

#### 9.2.1. Information with regard to physical hazard classes

No information available

#### 9.2.2. Other safety characteristics

No information available

### Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

No data available. Reactivity

10.2. Chemical stability

Stability Stable under normal conditions.

**Explosion data** 

Sensitivity to Mechanical Impact No data available. Sensitivity to Static Discharge No data available.

### 10.3. Possibility of hazardous reactions

No information available. Possibility of hazardous reactions

10.4. Conditions to avoid

Conditions to avoid None known.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

### 10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

### Section 11: TOXICOLOGICAL INFORMATION

#### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

The information included in this section describes the potential hazards of the individual **General Information:** 

ingredients

**Short term** May cause eye irritation (based on components) May produce allergic reactions following

skin contact.

**Known Clinical Effects:** Clinical use of this drug has caused hemorrhage gastrointestinal bleeding increased

bleeding time Individuals sensitive to this material or other materials in its chemical class

may develop allergic reactions.

**Acute toxicity** Serious eye damage/eye irritation

Skin corrosion/irritation

Respiratory or skin sensitization

Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met. Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met.

STOT - single exposure Based on available data, the classification criteria are not met.

Page 7/10

Product Name HEPARIN SODIUM- heparin sodium injection, solution

(Hospira, Inc.)

Revision date 07-Oct-2022 Version 2

STOT - repeated exposure
Reproductive toxicity
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.
Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

**Dalteparin Sodium (Heparin Sodium)** 

Rat Oral LD 50 > 5000 mg/kg Mouse Oral LD 50 > 5000 mg/kg

Mouse Intraperitoneal LD 50 > 2500 mg/kg Rat Intraperitoneal LD 50 2500 mg/kg Mouse Intravenous LD 50 2800 mg/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m<sup>3</sup>

Rat Oral LD 50 3 g/kg Mouse Oral LD 50 4 g/kg Rabbit Dermal LD 50 > 10 g/kg

Edetate disodium

Rat Oral LD50 2000-2200 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg ( Rat )	-	-
Dalteparin Sodium (Heparin Sodium)	> 779000 IU/kg (Rat)	-	-
SODIUM CHLORIDE	= 3 g/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat)1 h
Edetate disodium	= 2 g/kg ( Rat )	-	-

**Acute Toxicity Comments:** 

A greater than symbol (>) indicates that the toxicity endpoint being tested was not

achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

**Dalteparin Sodium (Heparin Sodium)** 

Eye Irritation Rabbit Mild SODIUM CHLORIDE
Skin irritation Rabbit Mild Eye irritation Rabbit Mild

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

<u>Dalteparin Sodium (Heparin Sodium)</u>
Fertility and Embryonic Development Rat Subcutaneous 10 mg/kg/day NOAEL Fertility, Fetotoxicity
Embryo / Fetal Development Rat Intravenous 10,000 mg/kg/day LOAEL Fetotoxicity

Embryo / Fetal Development Rabbit Intravenous 2,500 mg/kg/day LOAEL Fetotoxicity

**Carcinogenicity**None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

11.2.2. Other information

Page 8/10

Product Name HEPARIN SODIUM- heparin sodium injection, solution

(Hospira, Inc.)

Revision date 07-Oct-2022 Version 2

Other adverse effects No information available.

### Section 12: ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should

be avoided.

**12.1. Toxicity** 

No information available

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

12.4. Mobility in soil

Mobility in soil No information available.

#### 12.5. Results of PBT and vPvB assessment

### PBT and vPvB assessment

Chemical name	PBT and vPvB assessment		
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does		
	not apply		
Edetate disodium	The substance is not PBT / vPvB		

#### 12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

### Section 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### **Section 14: TRANSPORT INFORMATION**

The following refers to all modes of transportation unless specified below.

Page 9/10

Product Name HEPARIN SODIUM- heparin sodium injection, solution

(Hospira, Inc.)

Revision date 07-Oct-2022 Version 2

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:
UN proper shipping name:
Not applicable
Not applicable
Not applicable
Not applicable
Not applicable
Not applicable
Environmental Hazard(s):
Not applicable

Special precautions for user: Not applicable

### Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
TSCA Present
EINECS 231-791-2
AICS Present

Dalteparin Sodium (Heparin Sodium)

CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
TSCA Present
EINECS Not Listed
AICS Present
Standard for Uniform Scheduling of Medicines and Schedule 4

Poisons (SUSMP)

SODIUM CHLORIDE

CERCLA/SARA Section 313 de minimus % Not Listed California Proposition 65 Not Listed TSCA Present EINECS 231-598-3 AICS Present

Edetate disodium

CERCLA/SARA Section 313 de minimus % Not Listed
California Proposition 65 Not Listed
TSCA Present
EINECS 205-358-3
AICS Present

#### **France**

Occupational Illnesses (R-463-3, France)

Chemical name	French RG number	Title
SODIUM CHLORIDE 7647-14-5	RG 78	-

### **European Union**

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

#### Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Page 10 / 10

Product Name HEPARIN SODIUM- heparin sodium injection, solution

(Hospira, Inc.)

Revision date 07-Oct-2022 Version 2

### **Persistent Organic Pollutants**

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Plant protection products directive (91/414/EEC)

Chemical name	Plant protection products directive (91/414/EEC)			
SODIUM CHLORIDE - 7647-14-5	Plant protection agent			

#### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory **EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

### Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

**Data Sources:** Publicly available toxicity information. Pfizer proprietary drug development information.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the

Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information.

Revision date 07-Oct-2022

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.